[The future of loco-regional treatment for advanced gastric cancer].
We have evaluated the result of neo-adjuvant chemotherapy for advanced gastric cancer to estimate the future of loco- regional therapy. Twenty patients with advanced gastric cancer accepted 2 courses of neo-adjuvant chemotherapy with S- 1 and cisplatin. In 13 patients (52%), chemotherapy could successfully control the growth of tumor. Thirteen patients with curative resection demonstrated a better survival (MST 682 days) than 12 patients with non-curative resection (MST 377 days). Neo-adjuvant chemotherapy using S-1 and cisplatin was an effective treatment for advanced gastric cancer. However, no survival benefit could be obtained for patients with non-curative resection. Administration of loco-regional treatment, such as intra peritoneal paclitaxel, should be considered for those cases with positive peritoneal cytology.
Nagahama
Takeshi
T
Dept. of Surgery, Tokyo Metropolitan Toshima Hospital.
Ando
Masayuki
M
Ganno
Hideaki
H
Ami
Katsunori
K
Fukuda
Akira
A
Maruyama
Michio
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D004338:Drug Combinations; D006801:Humans; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage / Q000627:therapeutic use*
D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D002945:Cisplatin